Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255602 | 1.00 | TSHR (0.50) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13849512 | 1.00 | TSHR (0.50) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL42203 | 1.00 | TSHR (0.50) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1442538 | 1.00 | TSHR (0.50) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL9842020 | 0.97 | TSHR (0.48) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| Water SCHEMBL28115835 | 0.97 | TSHR (0.48) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| Ammonia Solution, Strong SCHEMBL1333562 | 0.97 | TSHR (0.48) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18857848 | 0.92 | TSHR (0.43) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28297278 | 0.92 | TSHR (0.43) | TSHRTP53SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8458943 | 0.87 | TSHR (0.40) | TSHRTP53SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939841-B | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonyl amino-4- (3-chlorophenyl) butyric acid | 康化（上海）新药研发有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-117903045-A | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonyl amino-3- [4- (2-pyridine) phenyl ] propionic acid | 康化（上海）新药研发有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-116606223-A | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonyl amino-6, 6-dimethyl N-heptanoic acid | 康化（上海）新药研发有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-115260060-A | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonylamino-5, 5-dimethyl norleucine | 康化（上海）新药研发有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-112939841-A | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonylamino-4- (3-chlorphenyl) butyric acid | 康化（上海）新药研发有限公司 | 2021-06-11 | — | — | CN | claimed |
| JP-63192746-A | — | — | None | — | — | JP | disclosed |
| CN-112939841-B | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonyl amino-4- (3-chlorophenyl) butyric acid | 康化（上海）新药研发有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-112939841-B | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonyl amino-4- (3-chlorophenyl) butyric acid | 康化（上海）新药研发有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117903045-A | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonyl amino-3- [4- (2-pyridine) phenyl ] propionic acid | 康化（上海）新药研发有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117903045-A | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonyl amino-3- [4- (2-pyridine) phenyl ] propionic acid | 康化（上海）新药研发有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024075131-A1 | CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF | NATCO PHARMA LIMITED (IN) | 2024-04-11 | — | — | WO | disclosed |
| CN-116606223-A | Synthesis method of (2S) -2-N-fluorenylmethoxycarbonyl amino-6, 6-dimethyl N-heptanoic acid | 康化（上海）新药研发有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2014-08-21 | — | — | US | disclosed |
| US-20030158152-A1 | Protease inhibitors and their pharmaceutical uses | CRUZ-FIOCRUZ, FUNDACAO OSWALDO (BR) | 2003-08-21 | — | — | US | disclosed |
| EP-1335895-A2 | PROTEASE INHIBITORS AND THEIR PHARMACEUTICAL USES | Fundacao Oswaldo Cruz - Fiocruz (BR) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002042412-A2 | PROTEASE INHIBITORS AND THEIR PHARMACEUTICAL USES | Fundação Oswaldo Cruz - FIOCRUZ (BR) | 2002-05-30 | — | — | WO | disclosed |
| US-6320069-B1 | REACTING RACEMIC ALCOHOL WITH OPTICALLY ACTIVE AMINO ACID TO PRODUCE AMINO ACID ESTER, PERFORMING DIASTEREOMER RESOLUTION THEREON BY PROCESS SELECTED FROM CRYSTALLIZATION SEPARATION, COLUMN SEPARATION AND SIMULATED MOVING BED SEPARATION | TORAY INDUSTRIES, INC. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-0924180-A1 | PROCESSES FOR THE PREPARATION OF OPTICALLY ACTIVE KETONES | TORAY INDUSTRIES, INC. (JP) | 1999-06-23 | — | — | EP | disclosed |
| JP-S63192746-A | 3-CYANO-2-HYDROXYPROPYLTRIMETHYLAMMONIUM- DIACETYLTARTRATE AND PRODUCTION THEREOF | BITAMIN KENKYUSHO:KK | 1988-08-10 | — | — | JP | disclosed |
| US-3932429-A | Novel azabicyclo octane derivative and process for preparing same | TANABE SEIYAKU CO., LTD (JA) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | TSHR 4455/4885TP53 2/4885SLC1A3 4813/4885 |
| US-20030158152-A1 | Protease inhibitors and their pharmaceutical uses | PEPD, DNPEP, PREP | TSHR 4612/4885TP53 1385/4885SLC1A3 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.